Vir Biotechnology, Inc.宣布,在针对转移性前列腺癌患者的1期临床试验剂量扩展队列中,首例患者已开始接受其PSMA靶向、Pro-Xten®双掩蔽T细胞衔接器候选药物VIR-5500的治疗。该阶段旨在进一步评估药物的安全性和耐受性。
Vir Biotechnology, Inc.宣布,在针对转移性前列腺癌患者的1期临床试验剂量扩展队列中,首例患者已开始接受其PSMA靶向、Pro-Xten®双掩蔽T细胞衔接器候选药物VIR-5500的治疗。该阶段旨在进一步评估药物的安全性和耐受性。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.